GLP-1 Drugs Show Potential Beyond Obesity and Diabetes Treatment

New research highlights that GLP-1 drugs might offer more benefits than merely treating obesity and type 2 diabetes. This animal-based study suggests their potential to extend life span. Researchers at the University of California, Berkeley, discovered that administering semaglutide to female mice extended their life span by mitigating some harmful effects of aging. These findings were published in Nature on September 2.

According to Danica Chen, a study author and professor of metabolic biology, nutritional sciences, and toxicology at the University, these results could widen GLP-1 medicines’ applications to promote longevity in healthy aging individuals.

GLP-1s, known commonly as the weight loss drugs Ozempic and Wegovy, function by reducing obsessive thoughts about eating. They mimic a hormone that enhances fullness and slows digestion, effectively curbing appetite and stabilizing blood sugar levels. This has driven their popularity in treating obesity and type 2 diabetes. As of March 2026, one in eight Americans were utilizing these drugs, says Statista. Analysts note this increase correlates with a drop in U.S. obesity rates, though multiple factors contribute to this change.

What the Study Found

Researchers gave daily semaglutide injections to 20-month-old female mice and observed a life span increase from 742 days (median life expectancy of the control group) to 834 days. Treated mice also experienced a 24 percent reduction in appetite, lowered body weight, and decreased tissue weight.

“Semaglutide treatment improved physiological function, moderated aging markers, and influenced nutrient sensors and genetic regulators of aging,”

Chen elaborated.

While significant, some experts found these results expected. Richard DiMarchi, a chemistry professor at Indiana University, explained that this finding aligns with current expectations. However, he cautioned that in a period of intense focus on peptide therapeutics, a balanced view is essential for observations yet to be clinically validated.

“Human application is far more complex due to genetic diversity among humans,” DiMarchi cautioned. He emphasized the importance of safety, especially for extending life in healthy individuals.

Randy Seeley from the University of Michigan, who consulted for Novo Nordisk and Eli Lilly, supported the study’s outcomes. He noted existing data shows these drugs can reduce all-cause mortality, linking them to life span extension.

Could GLP-1s Extend Life?

According to Chen, the semaglutide treatment might prolong life partly by decreasing calorie intake but stated additional factors are likely involved and require more research.

Seeley also discussed potential impacts on cardiovascular health, initially worrying about increased heart rate among users. However, reduced cardiovascular risk was consistently observed with several GLP-1 agonists in different populations.

He mentioned benefits beyond mere weight loss and hinted at possible anti-inflammatory effects of GLP-1s. The mechanisms of these effects remain unclear. Questions arise over whether they directly act on immune cells, alter metabolic fuel utilization, or influence brain-regulated immune function. Research in this area continues to evolve.